Vivozon Healthcare Inc (082800) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Vivozon Healthcare Inc KRW 488, price KRW 2,960, upside -83.5%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Vivozon Healthcare Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 1,956 KRW – 10,636 KRW · fair‑value band 364.37 KRW – 728.75 KRW · the 2,960 KRW price screens above the 488.26 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Vivozon Healthcare in your weekly email
Every Wednesday you see whether Vivozon Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications.
Show more
Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications. It also provides LED set linear lamps, including panel lamps, down lights, and flood lights for residential, commercial, and industrial structures, as well as lights for parking lots. In addition, the company operates Echo House, a lighting show room that sells LED florescent lamps, LED flat lamps, LED PAR lamps, LED bulb lamps, and home LED lightings. The company was formerly known as Vivozon Healthcare, Inc. and changed its name to Vivozon Pharmaceutical Co., Ltd. in November 2022. Vivozon Pharmaceutical Co., Ltd. was founded in 2002 and is based in Yongin, South Korea.
Stock analysis
Vivozon Healthcare Inc (082800) currently trades at 2,960 KRW, while our model-based Fair Value estimate is 488.26 KRW, 83.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 364.37 KRW (bear) to 728.75 KRW (bull), the price of 2,960 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vivozon Healthcare Inc reported revenue of 59.3B KRW in FY2025 versus 57.7B KRW in FY2021, a compound +0.7%/yr. Reported net income was −32.4B KRW in FY2025.
Key figures
Market cap 155B KRW (≈ $115M) · P/S ratio 2.41 · Net margin −54.6% · Return on equity −1,315% · Return on assets (EBIT) −8.5% · Operating margin −37.7% · Revenue (TTM) 59.9B KRW · Revenue growth (YoY) +8.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −40% fair-value upside, at −84%, 082800 screens richer than that median.
Fair Value models
Bear 364.37 KRWFair Value 488.26 KRWBull 728.75 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.12/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−32.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Start year 2020 (pandemic). Over 10 years: −4.1% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−46.6% (2020) → −32.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 51 stocks
Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside−83.5% · Bottom 25%
Profitability
Return on assets−6.4% · Bottom 25%
Net margin (TTM)−126.7% · Bottom 25%
Operating margin (TTM)−37.7% · Bottom 25%
Growth and dividend
Revenue growth8.5% · Below median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)43· sector 55
PAST (return on equity)0· sector 10
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 26
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Vivozon Healthcare Inc (082800) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 488.26 KRW versus a price of 2,960 KRW, about −84% upside (overvalued).
What is the fair value of 082800?
Our model-based fair value for Vivozon Healthcare Inc is 488.26 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,960 KRW.
What is the quality score of 082800?
Vivozon Healthcare Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vivozon Healthcare Inc (082800)?
Our model-based price target is the fair value of 488.26 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 364.37 KRW, optimistic scenario 728.75 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Vivozon Healthcare Inc stock forecast for 2026?
Our models put fair value at 488.26 KRW, about −84% upside versus a price of 2,960 KRW (overvalued). Cautious scenario 364.37 KRW, optimistic scenario 728.75 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Vivozon Healthcare Inc (082800)?
Vivozon Healthcare Inc reported trailing-twelve-month revenue of about 59.9B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Vivozon Healthcare Inc (082800)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vivozon Healthcare Inc it is 488.26 KRW per share (as of Sep 24, 2026), against a price of 2,960 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Vivozon Healthcare Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 082800 trades above its calculated fair value: price 2,960 KRW, fair value 488.26 KRW, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 082800?
No. The price is what the market pays today (2,960 KRW); the fair value is what the company's own numbers justify (488.26 KRW). For Vivozon Healthcare Inc the two are 2,472 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Vivozon Healthcare Inc worth?
The market values Vivozon Healthcare Inc at about 155B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,960 KRW; our models calculate a fair value of 488.26 KRW per share.
What do the bullish and bearish scenarios say about 082800?
Our models span a range for Vivozon Healthcare Inc: cautious scenario 364.37 KRW, base 488.26 KRW, optimistic 728.75 KRW per share (as of Sep 24, 2026, price 2,960 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 082800 from its 52-week high?
Vivozon Healthcare Inc trades at 2,960 KRW, about 54% below its 52-week high of 6,366 KRW and 37% above the low of 2,155 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 488.26 KRW is for.
Which stocks are comparable to Vivozon Healthcare Inc?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vivozon Healthcare Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 2,960 KRW, calculated fair value 488.26 KRW (−84%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 082800 calculated?
We run Vivozon Healthcare Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 488.26 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Vivozon Healthcare Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vivozon Healthcare Inc (082800)?
The closing price on Oct 2, 2026 was 2,960 KRW. Our model-based fair value is 488.26 KRW, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vivozon Healthcare Inc right now?
The price sits above even our optimistic bull case (728.75 KRW). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (364.37 KRW to 728.75 KRW) leaves room in how you read the outcome.
Key figures of Vivozon Healthcare Inc
How large is the market capitalisation of Vivozon Healthcare Inc (082800)?
The market capitalisation of Vivozon Healthcare Inc is 155B KRW (≈ $115M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vivozon Healthcare Inc (082800)?
The price-to-sales ratio of Vivozon Healthcare Inc is 2.41 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Vivozon Healthcare Inc (082800)?
The net margin of Vivozon Healthcare Inc is −54.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vivozon Healthcare Inc (082800)?
The return on equity (ROE) of Vivozon Healthcare Inc is −1,315% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vivozon Healthcare Inc (082800)?
On an EBIT basis the return on assets of Vivozon Healthcare Inc is −8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vivozon Healthcare Inc (082800)?
The operating margin of Vivozon Healthcare Inc is −37.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vivozon Healthcare Inc (082800)?
Revenue at Vivozon Healthcare Inc is growing +8.5% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vivozon Healthcare Inc (082800) generate?
The free cash flow of Vivozon Healthcare Inc is −9.1B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vivozon Healthcare Inc (082800) carry?
The net debt of Vivozon Healthcare Inc is 37.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vivozon Healthcare Inc in the live analysis
One click puts Vivozon Healthcare Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
